Open Label, Safety, Tolerability and Efficacy of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
| Status: | Completed |
|---|---|
| Conditions: | Parkinsons Disease |
| Therapuetic Areas: | Neurology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 4/21/2016 |
| Start Date: | October 2010 |
| End Date: | October 2013 |
An Open-label Treatment Study to Evaluate the Safety, Tolerability and Efficacy of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
The purpose of this study is to generate long-term safety, tolerability and efficacy data
for AFQ056 in patients who have participated in and completed any AFQ056 phase II study in
PD-LID (Parkinson's disease, L-dopa induced dyskinesias).
for AFQ056 in patients who have participated in and completed any AFQ056 phase II study in
PD-LID (Parkinson's disease, L-dopa induced dyskinesias).
Inclusion Criteria:
- Outpatients with Parkinson's disease (PD), treated with L-Dopa, experiencing
dyskinesias who have been eligible for, participated in and completed an AFQ056 phase
II core study.
Exclusion Criteria:
- Surgical treatment for PD
- Cancer within the past 5 years (other than localized skin cancer and prostate cancer
that has been effectively treated)
- Advanced, severe or unstable disease (other than PD) that may interfere with the
study outcome evaluations
Other protocol-defined inclusion/exclusion criteria may apply
We found this trial at
4
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials